metronidazole has been researched along with Metabolic Syndrome in 4 studies
Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.
metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.
Metabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ye, Z | 1 |
| Cao, Y | 1 |
| Miao, C | 1 |
| Liu, W | 1 |
| Dong, L | 1 |
| Lv, Z | 1 |
| Iheozor-Ejiofor, Z | 1 |
| Li, C | 1 |
| Liou, JM | 1 |
| Chen, CC | 2 |
| Chang, CM | 1 |
| Fang, YJ | 1 |
| Bair, MJ | 1 |
| Chen, PY | 1 |
| Chang, CY | 1 |
| Hsu, YC | 1 |
| Chen, MJ | 1 |
| Lee, JY | 1 |
| Yang, TH | 1 |
| Luo, JC | 1 |
| Chen, CY | 1 |
| Hsu, WF | 1 |
| Chen, YN | 1 |
| Wu, JY | 1 |
| Lin, JT | 1 |
| Lu, TP | 1 |
| Chuang, EY | 1 |
| El-Omar, EM | 1 |
| Wu, MS | 1 |
| Ünal, E | 1 |
| Güvendi Akçınar, U | 1 |
| Arduç, A | 1 |
| López, NJ | 1 |
| Quintero, A | 1 |
| Casanova, PA | 1 |
| Ibieta, CI | 1 |
| Baelum, V | 1 |
| López, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Non-surgical Periodontal Treatment on Plasma Fibrinogen, Plasminogen Activator Inhibitor 1 and C-reactive Protein Levels in Cardiovascular Disease Patients With Periodontitis[NCT04305171] | 28 participants (Actual) | Observational [Patient Registry] | 2018-04-06 | Completed | |||
| A Randomized Control Trial of Comprehensive Oral Intervention in Patients With Acute Myocardial Infarction: a Pilot Study[NCT04012541] | 68 participants (Anticipated) | Interventional | 2019-07-05 | Recruiting | |||
| Systemic Effects of Periodontal Therapy on Patients With Ischemic Stroke. A Pilot Randomized Controlled Clinical Trial[NCT04956211] | 60 participants (Anticipated) | Interventional | 2021-09-29 | Enrolling by invitation | |||
| The Effects of Non-Surgical Periodontal Therapy on Neutrophil Elastase and Elastase Alpha-1 Proteinase Inhibitor Levels in GCF in Periodontitis Patients With or Without Acute Coronary Syndrome[NCT04785235] | 43 participants (Actual) | Observational [Patient Registry] | 2007-10-15 | Completed | |||
| Comparison of the Efficacy of Clarithromycin-based Triple Therapy Versus Quadruple Therapies in the First Line Therapy of Helicobacter Pylori Infection- A Multicenter Randomized Comparative Trial[NCT01906879] | Phase 4 | 1,620 participants (Anticipated) | Interventional | 2013-06-30 | Recruiting | ||
| Comparative Recurrence Rate Investigation of Esomeprazole Versus Lansoprazole in Triple-Combination Therapy to Eradicate Helicobacter Pylori Infection Among Pediatrics: Multicentre, Randomized, and Controlled Trials[NCT05861687] | Phase 2/Phase 3 | 51 participants (Actual) | Interventional | 2021-08-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for metronidazole and Metabolic Syndrome
| Article | Year |
|---|---|
Periodontal therapy for primary or secondary prevention of cardiovascular disease in people with periodontitis.
Topics: Amoxicillin; Anti-Bacterial Agents; Cardiovascular Diseases; Chronic Periodontitis; Humans; Metaboli | 2022 |
Periodontal therapy for primary or secondary prevention of cardiovascular disease in people with periodontitis.
Topics: Amoxicillin; Anti-Bacterial Agents; Cardiovascular Diseases; Chronic Periodontitis; Humans; Metaboli | 2022 |
Periodontal therapy for primary or secondary prevention of cardiovascular disease in people with periodontitis.
Topics: Amoxicillin; Anti-Bacterial Agents; Cardiovascular Diseases; Chronic Periodontitis; Humans; Metaboli | 2022 |
Periodontal therapy for primary or secondary prevention of cardiovascular disease in people with periodontitis.
Topics: Amoxicillin; Anti-Bacterial Agents; Cardiovascular Diseases; Chronic Periodontitis; Humans; Metaboli | 2022 |
Periodontal therapy for primary or secondary prevention of cardiovascular disease in people with periodontitis.
Topics: Amoxicillin; Anti-Bacterial Agents; Cardiovascular Diseases; Chronic Periodontitis; Humans; Metaboli | 2022 |
Periodontal therapy for primary or secondary prevention of cardiovascular disease in people with periodontitis.
Topics: Amoxicillin; Anti-Bacterial Agents; Cardiovascular Diseases; Chronic Periodontitis; Humans; Metaboli | 2022 |
Periodontal therapy for primary or secondary prevention of cardiovascular disease in people with periodontitis.
Topics: Amoxicillin; Anti-Bacterial Agents; Cardiovascular Diseases; Chronic Periodontitis; Humans; Metaboli | 2022 |
Periodontal therapy for primary or secondary prevention of cardiovascular disease in people with periodontitis.
Topics: Amoxicillin; Anti-Bacterial Agents; Cardiovascular Diseases; Chronic Periodontitis; Humans; Metaboli | 2022 |
Periodontal therapy for primary or secondary prevention of cardiovascular disease in people with periodontitis.
Topics: Amoxicillin; Anti-Bacterial Agents; Cardiovascular Diseases; Chronic Periodontitis; Humans; Metaboli | 2022 |
Periodontal therapy for primary or secondary prevention of cardiovascular disease in people with periodontitis.
Topics: Amoxicillin; Anti-Bacterial Agents; Cardiovascular Diseases; Chronic Periodontitis; Humans; Metaboli | 2022 |
Periodontal therapy for primary or secondary prevention of cardiovascular disease in people with periodontitis.
Topics: Amoxicillin; Anti-Bacterial Agents; Cardiovascular Diseases; Chronic Periodontitis; Humans; Metaboli | 2022 |
Periodontal therapy for primary or secondary prevention of cardiovascular disease in people with periodontitis.
Topics: Amoxicillin; Anti-Bacterial Agents; Cardiovascular Diseases; Chronic Periodontitis; Humans; Metaboli | 2022 |
Periodontal therapy for primary or secondary prevention of cardiovascular disease in people with periodontitis.
Topics: Amoxicillin; Anti-Bacterial Agents; Cardiovascular Diseases; Chronic Periodontitis; Humans; Metaboli | 2022 |
Periodontal therapy for primary or secondary prevention of cardiovascular disease in people with periodontitis.
Topics: Amoxicillin; Anti-Bacterial Agents; Cardiovascular Diseases; Chronic Periodontitis; Humans; Metaboli | 2022 |
Periodontal therapy for primary or secondary prevention of cardiovascular disease in people with periodontitis.
Topics: Amoxicillin; Anti-Bacterial Agents; Cardiovascular Diseases; Chronic Periodontitis; Humans; Metaboli | 2022 |
Periodontal therapy for primary or secondary prevention of cardiovascular disease in people with periodontitis.
Topics: Amoxicillin; Anti-Bacterial Agents; Cardiovascular Diseases; Chronic Periodontitis; Humans; Metaboli | 2022 |
2 trials available for metronidazole and Metabolic Syndrome
| Article | Year |
|---|---|
Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Body Mass Index; Clarithromycin; Disease Eradicatio | 2019 |
Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Body Mass Index; Clarithromycin; Disease Eradicatio | 2019 |
Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Body Mass Index; Clarithromycin; Disease Eradicatio | 2019 |
Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Body Mass Index; Clarithromycin; Disease Eradicatio | 2019 |
Effects of periodontal therapy on systemic markers of inflammation in patients with metabolic syndrome: a controlled clinical trial.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Atherosclerosis; Biomarkers; Blood Glucose; Body Ma | 2012 |
1 other study available for metronidazole and Metabolic Syndrome
| Article | Year |
|---|---|
Hidradenitis Suppurativa, Metabolic Syndrome, and Demodex spp. Infestation.
Topics: Administration, Cutaneous; Administration, Oral; Animals; Anti-Bacterial Agents; Antiparasitic Agent | 2018 |